🔎 HARMONi-GI1 | Safety

Gr3–4 AEs: 82.0% ivonescimab+GemCis vs 72.3% durva+GemCis

Serious AEs similar (43.4% vs 43.7%); gr ≥3 IO-related AEs 4.1% in both

Could dual PD-1/VEGF reshape 1L BTC treatment? Longer followup &validation beyond this trial population needed

#ESMO26